UWorld LLC v. USMLE Galaxy LLC

CourtDistrict Court, N.D. Texas
DecidedApril 24, 2025
Docket3:23-cv-00447
StatusUnknown

This text of UWorld LLC v. USMLE Galaxy LLC (UWorld LLC v. USMLE Galaxy LLC) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
UWorld LLC v. USMLE Galaxy LLC, (N.D. Tex. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION UWORLD LLC f/k/a USMLEWORLD § LLC, § § Plaintiff, § § No. 3:23-cv-447-K-BN V. § § USMLE GALAXY LLC d/b/a § ARCHER REVIEW and TART LABS, § § Defendants. § MEMORANDUM OPINION AND ORDER Plaintiff UWorld, LLC f/k/a USMLEWorld, LLC has filed a Motion for Leave to Take Additional Depositions under Federal Rule of Civil Procedure 30(a)(2)(A), specifically of the corporate representative for Non-party Leeds Equity Partners and Jacques Galante. See Dkt. No. 239. For the reasons explained below, the Court grants UWorld’s Motion for Leave to Take Additional Depositions [Dkt. No. 239]. Background UWorld explains that it has taken, by its count, only seven depositions in this case: (1) Defendant USMLE Galaxy LLC d/b/a Archer Review’s corporate representative Dr. Karthik Koduru (by June 2023 deposition for the purposes of the preliminary injunction dispute, and a February 2025 deposition on the merits); (2) Defendant Tart Labs’s corporate representative Gowtham Raj Prabu (by a May 2024 deposition limited to the personal jurisdiction dispute and a March 2025 deposition on the merits); (3) Morgan Taylor; (4) David Cox; (5) the corporate representative for a potential acquisition of Archer Review; (6) Tiffany Kwong; and (7) Dr. Pranathi Koduru. And UWorld seeks to add two additional depositions to that list: (8) Non-party Leeds Equity Partners’s corporate representative; and (9) fact witness Jacques Galante. UWorld argues that: • the two Tart Labs Federal Rule of Civil Procedure 30(b)(6) corporate representative depositions (one for personal jurisdiction and one on the merits) should count as one toward Federal Rule of Civil Procedure 30(a)(2)(A)(i)’s ten-deposition limit because Tart Labs blocked questions outside the limited scope of the jurisdiction in the initial May 2024 deposition and, so, the March 2025 deposition of Tart Labs should be treated as a continuation of the prior deposition; • the Archer Review Federal Rule of Civil Procedure 30(b)(6) corporate representative depositions (one for the preliminary injunction dispute and one on the merits) and Tart Labs Federal Rule of Civil Procedure 30(b)(6) corporate representative depositions should also count as one each because they involved an entity, not an individual, and because, as various district courts have held, a corporation can be re-deposed without leave of court under Federal Rule of Civil Procedure 30(a)(2)(A)(ii) and, so, because leave of court was not necessary under Rule 30(a)(2)(A)(ii) to re-depose Archer Review or Tart Labs, no leave is needed under Rule 30(a)(2)(A)(i); and, • where UWorld served Dr. Karthik Koduru with both Federal Rule of Civil Procedure 30(b)(6) and Federal Rule of Civil Procedure 30(b)(1) notices before his February 2025 deposition, UWorld conducted a single deposition of Dr. Koduru, taken during the same less-than-seven-hour period and resulting in one transcript, which should count as one deposition toward Rule 30(a)(2)(A)(i)’s ten-deposition limit. And, UWorld asserts that, even if the Court disagrees and finds that one of these depositions should count as two depositions, UWorld would still be at eight depositions with room still remaining to take the two depositions of Leeds Equity Partners’s corporate representative and Jacques Galante. But, UWorld contends that, even if these two additional depositions would cause it to exceed the ten-deposition limit, UWorld should be allowed to take these two additional depositions because they concern new discovery material to the case and because all of UWorld’s prior depositions were necessary.

Archer Review and Tart Labs disagree with most of UWorld’s position and contentions, do not stipulate to UWorld’s taking these two additional depositions, and contend that UWorld has taken nine depositions in this case – on nine different notices at nine different points in time. By Archer Review and Tart Labs’s count, UWorld has already deposed: (1) Archer Review’s corporate representative Dr. Karthik Koduru on June 9, 2023; (2) Tart Labs’s corporate representative Gowtham Raj Prabu on May 1, 2024; (3) Morgan Taylor on August 22, 2024; (4) David Cox on September 11, 2024; (5) Tiffany Kwong on September 20, 2024; (6) Matthew Riley on October 2, 2024; (7) Dr. Pranathi Koduru on December 3, 2024; (8) Archer Review’s corporate representative Dr. Karthik Koduru on February 18, 2025; and (9) Tart Labs’s corporate representative Gowtham Raj Prabu on March 4, 2025. Archer Review and Tart Labs contend that UWorld should be limited to at most taking only one additional deposition because UWorld fails to show the necessity of all of the depositions that it has previously taken – specifically, the depositions of Tiffany Kwong and Dr. Pranathi Koduru – and of the two additional depositions that it seeks. And, so, Archer Review and Tart Labs assert, UWorld should be denied leave to exceed Rule 30(a)(2)(A)(i)’s ten-deposition limit. In reply, UWorld contends that it is entitled to take Jacques Galante’s deposition within the ten-deposition limit because Archer Review and Tart Labs’s count of nine depositions double-counts the Tart Labs deposition and that, if the Court agrees that the deposition of Tart Labs is one deposition, UWorld may take the two additional depositions that it seeks without exceeding the ten-deposition limit, rendering this motion moot. But, UWorld adds that, to streamline the process and

avoid unnecessary disputes, UWorld is willing – if the Court disagrees with UWorld’s position – to withdraw the notice for Jacques Galante’s deposition if Mr. Galante serves as the corporate representative for Leeds Equity Partners. Legal Standards and Analysis Federal Rule of Civil Procedure 30(a)(2)(A)(i) limits each side in a case – that is, the plaintiffs, the defendants, or the third-party defendants – to taking ten deposition without the Court’s leave. And one of the key questions that UWorld’s motion raises is whether a

successive Rule 30(b)(6) corporate representative deposition with topics different from the earlier Rule 30(b)(6) deposition counts as an additional deposition toward Rule 30(a)(2)(A)(i)’s ten-deposition limit. But, to properly answer that question and assess the parties’ conflicting arguments and differing counts as to how many depositions UWorld has taken in this case so far, the Court must analyze Federal Rules of Civil Procedure 30(a)(2)(A)(i), 30(a)(2)(A)(ii), and 30(b)(6) and how they interact.

I. Federal Rule of Civil Procedure 30 and its Advisory Committee Notes Federal Rule of Civil Procedure 30 provides in relevant part: (a) When a Deposition May Be Taken. (1) Without Leave.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
UWorld LLC v. USMLE Galaxy LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/uworld-llc-v-usmle-galaxy-llc-txnd-2025.